Qianjiang Yongan Pharmaceutical Co., Ltd. (SZSE: 002365)
Health Care · Pharmaceuticals · CN
CN¥16.59
+25.49% today · -16.9% 1Y
Qianjiang Yongan Pharmaceutical Co., Ltd. (SZSE: 002365) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $713.57M and employs 912 people.
Over the last twelve months the share price has lost 16.9%, trading between 9.82 and 20.18.
Tweenvest scores Qianjiang Yongan Pharmaceutical Co., Ltd. across four factors: quality 67/100, value 16/100, growth 0/100, dividend 20/100. Its strongest factor is quality.
002365 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $713.57M
- Revenue (TTM)
- $122.93M
- P/E
- 138.72
- EPS
- 0.12
- Dividend yield
- 0.60%
- Beta (5Y)
- 0.29
- 52-week high
- CN¥20.18
- 52-week low
- CN¥9.82
- Avg volume (3M)
- —
- Shares outstanding
- 289.15M
- Employees
- 912
- Next earnings
- —
About Qianjiang Yongan Pharmaceutical Co., Ltd.
Qianjiang Yongan Pharmaceutical Co., Ltd. engages in production and sale of taurine in China. It produces ethylene oxide, polycarboxylic acid-based water reducer monomers, water reducers, and health products. The company engages in scientific research and technical service, creatine monohydrate, wholesale and retail trade, leasing and business services, and crop farming. Qianjiang Yongan Pharmaceutical Co., Ltd. was founded in 2001 and is based in Qianjiang, China.
- ISIN
- CNE100000LZ9
- Founded
- 2001
- Listed since
- Mar 5, 2010
- Exchange
- Shenzhen Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.24 | +1.07% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF375.60 | +1.02% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £122.40 | +1.26% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.07 | +1.01% |
Figures last refreshed Aug 18, 2026.